about
Current targeted therapies in the treatment of advanced colorectal cancer: a reviewMolecular concept in human oral cancerPersonalized treatment for advanced colorectal cancer: KRAS and beyondCellular and molecular motions: order and disorderMolecular therapy of colorectal cancer: progress and future directionsAllele Frequencies of the Epidermal Growth Factor Receptors Polymorphism R521K in Colorectal Cancer Patients and Healthy Subjects Indicate a Risk-Reducing Effect of K521 in Syrian PopulationA chemocentric approach to the identification of cancer targetsRandomized controlled trial to evaluate the effects of ethyl-2-cyanoacrylate on pain intensity and quality of life in head and neck cancer patients suffering from cetuximab-induced rhagades during radioimmunotherapy: the support trial.A novel glycoengineered bispecific antibody format for targeted inhibition of epidermal growth factor receptor (EGFR) and insulin-like growth factor receptor type I (IGF-1R) demonstrating unique molecular properties.Autocrine motility factor modulates EGF-mediated invasion signaling.Antibody phage display libraries: contributions to oncology.The tyrosine phosphatase PTPRO sensitizes colon cancer cells to anti-EGFR therapy through activation of SRC-mediated EGFR signalingRisk/benefit profile of panitumumab-based therapy in patients with metastatic colorectal cancer: evidence from five randomized controlled trials.Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.Prevalence of KRAS, BRAF, PI3K and EGFR mutations among Asian patients with metastatic colorectal cancerCombined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer.Antiepidermal growth factor receptor monoclonal antibodies: applications in colorectal cancer.Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances.JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitorsGene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer.Oncologic Photodynamic Therapy: Basic Principles, Current Clinical Status and Future Directions.Photoimmunotherapy: comparative effectiveness of two monoclonal antibodies targeting the epidermal growth factor receptor.Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Individualized therapy for metastatic colorectal cancer.MicroRNAs targeting EGFR signalling pathway in colorectal cancer.Impact of cetuximab in current treatment of metastatic colorectal cancer.Mechanism-based cancer therapy: resistance to therapy, therapy for resistance.Do TRPV1 antagonists increase the risk for skin tumourigenesis? A collaborative in vitro and in vivo assessment.Visible to Near-Infrared Fluorescence Enhanced Cellular Imaging on Plasmonic Gold Chips.Cotargeting EGFR and autophagy signaling: A novel therapeutic strategy for non-small-cell lung cancer.Expression of anoctamin 1 is associated with advanced tumor stage in patients with non-small cell lung cancer and predicts recurrence after surgery.EGFR as a predictor of relapse in myxopapillary ependymoma.Prognosis and Therapeutic Implications for Emerging Colorectal Cancer Subtypes
P2860
Q26740067-149F5349-F798-42E1-8396-ABB7CC819AE8Q26775850-558B4087-DC7E-46AA-AB75-9857CB941118Q26822817-334E3AC7-1DBE-405D-8BD2-339469752AC8Q26999665-E6D9F0FF-3CFE-42F8-8CEB-702B7D2941E3Q27005764-34A2E454-1BC7-42A0-938E-76EA0B8E5376Q28397131-8B29E54F-5592-490D-947E-B4C39D9DBD2BQ28482507-7ECEA401-CD69-4DBB-B812-59B7AE3E848FQ33733218-20179E0C-96BA-4852-88D0-4B569D5A7146Q33846405-42260A19-659D-4C8D-8B5D-A8F7F2938863Q33881000-BC405D0A-E1F8-4970-88A7-E7F503D77B80Q34323991-E980A14F-AA81-4B44-AEE9-0E2B12C6F0AEQ34654408-58AEADC2-00F8-4F55-92F6-867ABBEA6889Q35211367-1FD44654-8E02-4BD4-BD28-68124267D423Q35238436-EE64BA13-83FA-4813-AFC9-E561358AA2BFQ36085837-2A5729BF-5FE1-4504-86B6-729488549E17Q36195351-B5E9EF46-CB38-4219-AC7A-6590F8908BE5Q36321184-C605A5B4-EA65-413F-93F6-6C5EDF86A06AQ36589179-C5829B16-0457-43C1-9F0F-B6132BF8AC15Q37107598-A3745474-283F-471C-BD8A-7E9530D95E7AQ37343279-FA472F23-B70F-4B8E-9138-DAB204622870Q37676077-74D23B4B-5BC6-43AA-9EB6-BB37AE6C0B83Q37732381-3DD8860E-94F1-4E98-85C7-BF1D876322E1Q38071119-62A5BC0A-FC9E-4D09-B998-E76BA87679F6Q38092886-BB0AC804-CF40-46A3-9B5C-3171AB1FDE46Q38118612-32D89C2C-EDE9-469F-A0A2-F3EFC78D8687Q38183447-70F2A1FF-7B4F-4805-8274-E0D39D63C1CEQ38255064-875F463B-A2DD-437B-A519-FDEF8BB72F6DQ38621035-2C60A5C1-C81D-4865-8FDD-8CC62E0059B7Q38811907-4DDC37ED-140F-4671-97B1-D57571A8A5DBQ42583016-6BE79CBE-5E1B-4F9F-B1A0-51D0F7A91C82Q51097682-539C2758-7319-41F8-B1D0-9A132992BD5CQ54541437-6DEC9E61-4F6F-41EC-8CC1-3DE4D8A11B6FQ58614422-78570637-8AE0-403B-8C31-F4CE276E9CC1
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
EGFR-targeted therapy.
@en
EGFR-targeted therapy.
@nl
type
label
EGFR-targeted therapy.
@en
EGFR-targeted therapy.
@nl
prefLabel
EGFR-targeted therapy.
@en
EGFR-targeted therapy.
@nl
P50
P1476
EGFR-targeted therapy.
@en
P2093
Loredana Vecchione
P304
P356
10.1016/J.YEXCR.2011.08.021
P407
P577
2011-09-07T00:00:00Z